A pandemic-related shortage of a mundane item – tubes to collect blood samples from patients -- has caused headaches for health systems worldwide. But it may also have a silver lining: A lesson in how to reduce unneeded medical tests, whether or not there’s a shortage, according to a new study.
Researchers at Stanford University have developed “decoy receptor” molecules that inhibit the growth of both multiple myeloma (MM) and diffuse large B cell lymphoma (DLBCL) in mice. The molecules, described in a study to be published July 26 in the Journal of Experimental Medicine (JEM), were also found to be nontoxic in monkeys, suggesting they could be used to treat humans with either of these deadly diseases, which are two of the most common blood cancers around the world.
Rhinostics introduces another breakthrough in automated sample collection technologies with the launch of the patent-pending VERIstic™ Collection Device focused on small volume blood collection.
DiaSorin (FTSE MIB: DIA) announced today the FDA 510(k) clearance and the commercial launch in the US of the host-protein signature-based assay LIAISON® MeMed BV®
Patients are 20% less likely to die of sepsis because a new AI system developed at Johns Hopkins University catches symptoms hours earlier than traditional methods, an extensive hospital study demonstrates.
The system, created by a Johns Hopkins researcher whose young nephew died from sepsis, scours medical records and clinical notes to identify patients at risk of life-threatening complications. The work, which could significantly cut patient mortality from one of the top causes of hospital deaths worldwide, is published today in Nature Medicine and Nature Digital Medicine.
KT-8000 is equipped with auto-loader and sample mixer. This brand new fully automated hematology analyzer can free your hands and extend walk-away time. Smart counting mode can fit into more application scenarios than other hematology analyzers. Support both open vial/auto loading mode, and emergency sample first, and fit all the demands. Powerful data management unit has improved the work efficiency markedly.
Sysmex America products on display throughout the Expo at Booth #2802 in Chicago; Product Demonstrations and Educational Opportunities throughout the Show
In this study, researchers at Beth Israel Deaconess Medical Center found that Black adults underwent significantly more endovascular peripheral vascular interventions (PVI), were treated for more advanced disease and were also more likely to experience adverse outcomes following PVI procedures, including amputation and death.
A growing number of studies indicate short, repeated bouts of reduced circulation with a blood pressure cuff may help reduce tissue damage and prevent the worst outcomes of heart attacks and strokes.
Caregivers for patients with multiple myeloma may suffer from higher rates of anxiety and depression than patients themselves, according to a new study published today in Blood Advances.
A novel, disease-modifying therapy for Alzheimer’s disease may involve the whole exchange of blood, which effectively decreased the formation of amyloid plaque in the brains of mice, according to a new study from UTHealth Houston.
The discovery of 14 inherited genetic changes which significantly increase the risk of a person developing a symptomless blood disorder associated with the onset of some types of cancer and heart disease is published today in Nature Genetics. The finding, made in one of the largest studies of its kind through genetic data analysis on 421,738 people, could pave the way for potential new approaches for the prevention and early detection of cancers including leukaemia.
A biochemist from RUDN and IBMC has found a way to protect healthy leukocytes during leukemia chemotherapy. Small nitrogen-containing polyamine molecules give the necessary protection. They are synthesized by almost all living cells, but only in normal lymphocytes, they exhibit protective properties.
Background: Machine learning (ML) and deep learning (DL) methods have recently garnered a great deal of attention in the field of cancer research by making a noticeable contribution to the growth of predictive medicine and modern onc...
People who add extra salt to their food at the table are at higher risk of dying prematurely from any cause, according to a study of more than 500,000 people, published in the European Heart Journal today (Monday).
Blood pressure levels dropped significantly among Chinese adults with high blood pressure who ate a modified heart-healthy, lower sodium traditional Chinese cuisine for four weeks, according to new research published today in the American Heart Association’s flagship journal Circulation.
n a new paper, researchers from University Hospitals (UH) detail how they used data via a dashboard to decrease the use of packed red-blood cell (pRBC) transfusions and platelets with an increase in appropriate transfusions.
Their paper, “Transfusion Utilization and Appropriateness: Thinking Differently at a Tertiary Academic Medical Center,” appears in the July/August 2022 issue of the edition of the Physician Leadership Journal. (DOI: https://doi:10.55834/plj.1146877267)
An estimated one-quarter of adults in the U.S. have nonalcoholic fatty liver disease (NAFLD), an excess of fat in liver cells that can cause chronic inflammation and liver damage, increasing the risk of liver cancer. Now, UT Southwestern researchers have developed a simple blood test to predict which NAFLD patients are most likely to develop liver cancer.
The origins of our blood may not be quite what we thought. Using cellular “barcoding” in mice, a groundbreaking study finds that blood cells originate not from one type of mother cell, but two, with potential implications for blood cancers, bone marrow transplant, and immunology. Fernando Camargo, PhD, of the Stem Cell Program at Boston Children’s Hospital led the study, published in Nature on June 15.
Mount Sinai researchers have for the first time identified genes that predict a good response to a vital new therapy for a blood cancer that can have serious side effects for some patients.
A study from Karolinska Institutet in Sweden sheds new light on the question of whether the sex and previous pregnancy of blood donors affects survival in patients who receive red blood cell transfusions.
A new study by researchers at Washington University School of Medicine in St. Louis shows that treatment with an immunity boosting protein called interleukin 7 (IL-7) after an infusion of genetically modified T cells causes the cancer-fighting CAR-T cells to grow in number and become more effective at killing tumor cells.
An investigational drug taken while undergoing chemotherapy demonstrated superior overall survival compared to chemotherapy alone in adult patients with a common, highly aggressive subtype of acute myeloid leukemia (AML).
A new research describes how highly proliferative leukemia cells end up becoming normal cells that no longer multiply, by changing the chemical modifications -the so-called epigenetics- of a type of its genetic material: the messenger RNA.
Momelotinib, an oral pill taken once a day, significantly improved outcomes of patients treated for myelofibrosis (MF), a rare but fatal bone marrow cancer, researchers reported June 7. Ruben Mesa, MD, FACP, executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, presented results of the MOMENTUM phase 3 randomized study, which evaluated momelotinib against a second medication, danazol, in symptomatic and anemic MF patients previously treated with standard-of-care JAK inhibitor therapy.
On Tuesday, June 7, Eunice Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, will present the long-term results of a phase 2 clinical trial combining crenolanib, a second-generation FLT3 inhibitor, with standard intensive chemotherapy for treatment of adults with newly diagnosed FLT3-mutant acute myeloid leukemia (AML), in a talk at the American Society of Clinical Oncology (ASCO) annual meeting 2022.
A mysterious form of diabetes known as malnutrition-related diabetes afflicts tens of millions of people in Asian and sub-Saharan African countries. Its victims—mainly thin and impoverished adolescents and young adults—rarely live more than a year after diagnosis. Their young age and thinness suggest type 1 diabetes (T1D), but insulin injections usually don’t help and can even cause death from low blood sugar. Nor do patients seem to have type 2 diabetes (T2D), which is typically associated with obesity.
Instructors from the American College of Surgeons STOP THE BLEED® program are available for media interviews as the nation observes National STOP THE BLEED® Month in May.
Emergency Medicine and Trauma Surgery researchers at Vanderbilt University Medical Center (VUMC) are joining Vanderbilt LifeFlight in a Department of Defense (DOD)-funded clinical trial aimed at improving survival with resuscitation techniques used to keep patients alive after a traumatic injury.
A $2.3 million National Institutes of Health (NIH) grant will fund Jianjun Guan and Fuzhong Zhang’s effort to develop and deliver therapeutic proteins to help treat injured limbs.
An international team led by a University of Toronto researcher has found that an antibody detectable in blood predicts severe Crohn’s disease and is detectable up to seven years prior to disease diagnosis.
The American College of Surgeons (ACS) applauds Senators Menendez and Boozman and Representatives O’Halleran and Wenstrup for introducing the Prevent Blood Loss with Emergency Equipment Devices Act (Prevent BLEEDing Act). This legislation is crucial to support efforts to bring STOP THE BLEED® training and equipment directly to all U.S. citizens.
2011 changes in policies and recommendations related to the use of erythropoietin-stimulating agents were associated with lower hemoglobin levels and lower risks of major adverse cardiovascular events, mortality, and stroke among adults receiving hemodialysis, but with a higher risk of heart attack.
A test for the common blood cancer multiple myeloma also holds clear clues that the patient has one of the most uncommon and deadly forms of this cancer, investigators say.
A commonly used blood pressure medication may help improve measures of frailty in prefrail older adults, according to a new study by researchers with UTHealth Houston.
The study was published in The Journals of Gerontology.
Adolescent and young adult survivors of acute lymphoblastic leukemia and acute myeloid leukemia, two of the most common leukemias for ages 15 to 39 years old, have increased risk of mortality than the general population for decades after initial diagnosis. Researchers investigated disparities specific to survivorship to learn about patients’ outcomes after they survived their initial diagnosis; and analyzed data from cancer survivors who were at least five years post treatment. Results suggest there is a gap in critical data surveillance that needs to be examined to further understand what is impacting long-term survivorship for AYAs.
Ten years ago, Tom and Kari Whitehead came to Children’s Hospital of Philadelphia (CHOP) looking for a miracle. Their 6-year-old daughter, Emily, had relapsed in her battle with acute lymphoblastic leukemia (ALL), after many months of unsuccessful chemotherapy and a disease that had progressed so rapidly that she was ineligible for a bone marrow transplant to treat it. Her family came to CHOP in the hopes that Dr. Stephan Grupp, a pioneer in the field of cellular immunotherapy, could provide the miracle they were looking for.
妙佑医疗国际(Mayo Clinic) 个体化医学中心(Center for individualized Medicine )的新研究发现,携带ASXL1突变体的慢性粒单核细胞白血病(一种罕见骨髓癌)患者中存在独特的表观遗传变化,可激活有害基因并导致癌细胞更快生长。ASXL1基因突变还能使疾病转化为更具侵袭性的急性髓细胞性白血病。
Uma nova pesquisa do Centro de Medicina Individualizada da Mayo Clinic descobre que pacientes com leucemia mielomonocítica crônica com mutação ASXL1 (um tipo incomum de câncer de medula óssea) têm alterações epigenéticas específicas que podem ativar genes nocivos e fazer com que o câncer cresça mais rapidamente.
وجد بحث جديد من مركز مايو كلينك للطب الفردي أن المرضى المصابين بابيضاض الدم المايلومونيكي المزمن بسبب طفرة ASXL1 - وهو نوع غير شائع من سرطان نخاع العظم - لديهم تغييرات لاجينية مميزة يمكنها تنشيط الجينات الضارة وتتسبب في نمو السرطان بشكل أسرع. كما يمكن لطفرة ASXL1 الجينية تحويل المرض إلى ابيضاض الدم النقوي الحاد الأكثر عدوانية.
Las nuevas investigaciones del Centro para Medicina Personalizada de Mayo Clinic descubren que los pacientes con leucemia mielomonocítica crónica con mutación en el gen ASXL1, un tipo raro de cáncer de la médula ósea, sufren cambios epigenéticos distintivos que activan genes nocivos y hacen que el cáncer se desarrolle con más rapidez.
In Physics of Fluids, researchers present clinicians with information about the risk factors for atherosclerotic plaque formation from a mechanical point of view. The scientists are exploring whether it is possible to screen and intervene early for people at risk for atherosclerotic disease from the perspective of hemodynamics, using color Doppler ultrasound, coronary computed tomography angiography, and other screenings. The researchers used a multipoint, noncontact laser flow measurement method called microparticle image velocimetry.